AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02383160 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Placebo device with no active therapy
Study NCT02491879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: 2.5% Ketoprofen gel with a 2 g local use
Study NCT02491879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel with a 2 g local use
Study NCT01908283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugated vaccine (PCV13)
Description: Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
Study NCT02967731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 Mometasone Furoate Sinus Drug Depot
Description: Management of Chronic Sinusitis
Study NCT00662246 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: respiratory gated proton beam radiotherapy
Description: - Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
Study NCT01737866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 423
Description: omecamtiv mecarbil
Study NCT01541631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40mg/kgBWT Albendazole - 400mg once
Study NCT00377910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aethoxysclerol
Description: 2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
Study NCT03324789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Implant Partial Over-denture
Description: Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
Study NCT03324789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Partial Denture
Description: patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
Study NCT02408744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
Study NCT00089492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background ARVs
Description: As prescribed
Study NCT01045421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN8237 (Alisertib)
Description: Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period.
Study NCT00804141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-methylnaltrexone bromide (MOA-728)
Description: MOA-728 will be administered as per the dose and schedule specified in the arm.
Study NCT05666947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: Eight weeks of home-based exercise programs
Study NCT05666947 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home-based exercise
Description: Eight weeks of home-based exercise programs
Study NCT05378919 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 50 Gy
Description: Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks
Study NCT05378919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil/folic acid
Description: Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
Study NCT05378919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)
Description: oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
Study NCT05378919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 50 Gy
Description: Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil.
Study NCT02575612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vacuum-assisted biopsy
Description: Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (> 50 ultrasound guided minimal invasive biopsies per year, > 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
Study NCT00089492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Background ARVs
Description: As prescribed
Study NCT00089492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 180mg sc once daily for 48 weeks
Study NCT00089492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid for 48 weeks
Study NCT01172028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere (Docetaxel)
Description: Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
Study NCT01172028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta (Pemetrexed)
Description: ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
Study NCT02482311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD 1775
Description: AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food.
Study NCT03545672 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CMR examination
Description: After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
Study NCT04573855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 immunoglobulin
Description: Treatment with Anti-SARS-CoV-2 immunoglobulin
Study NCT03528317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate day fasting
Description: Alternate day fasting with a high protein diet
Study NCT02772029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
Study NCT01912014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support and counselling
Study NCT00377910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aethoxysclerol
Description: 2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
Study NCT01236313 — intervention group
Intervention type: PROCEDURE
Intervention: TEE report
Description: Information will be collected during cardiac surgery.
Study NCT00318123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kivexa
Description: abacavir 600mg + lamivudine 300mg in one tablet QD
Study NCT00007683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin titrated to an INR of 2.5-3.0
Description: anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
Study NCT00007683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
Study NCT00007683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75
Description: (an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
Study NCT04099147 — intervention group
Intervention type: OTHER
Intervention: This is an observational study.
Description: This is an observational study. No intervention is planned outside of usual clinical practice.
Study NCT01116115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: InFat™ based infant formula
Description: High sn-2 palmitic acid oil based infant formula
Study NCT01116115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard vegetable oil based infant formula
Description: Standard vegetable oil based infant formula
Study NCT04256525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10mg
Description: 10mg orally per day
Study NCT04256525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: 100mg orally per day
Study NCT04256525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecule heparin
Description: 0.4ml per day subcutaneous injection
Study NCT02862574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via subcutaneous injection once weekly
Study NCT02862574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous injection once weekly
Study NCT02862574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection once weekly
Study NCT02862574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally weekly as part of the participant's current treatment regimen
Study NCT02862574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally weekly as part of the participant's current treatment regimen
Study NCT02862574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor
Description: An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
Study NCT01238510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent technique: Provisional fKBT
Description: Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.~Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only
Study NCT01429077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
Study NCT01429077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
Study NCT04205578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dl-3-n-butylphthalide (NBP)
Description: 25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
Study NCT04205578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution
Description: 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
Study NCT04090905 — intervention group
Intervention type: OTHER
Intervention: Standard clinical monitoring
Description: Standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
Study NCT04090905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Holter monitoring
Description: Cardiac rhythm monitoring before, during, and until hospital discharge (preferably ≥72 hours after abdominal surgery)
Study NCT03741725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pay-it-forward
Description: Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
Study NCT03741725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pay-what-you-want
Description: Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
Study NCT00974051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: Oral (2.5mg) one time administration at 9:00pm
Study NCT00974051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% basal insulin reduction
Description: Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
Study NCT01541631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
Study NCT01541631 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Praziquantel and Albendazole
Description: Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
Study NCT03809312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin / Clavulanic acid 875mg / 125mg
Description: Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
Study NCT00974051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No treatment is given for the study. This arm is for comparison with the two intervention arms.
Study NCT03822871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1403
Description: Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
Study NCT03822871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1057
Description: Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
Study NCT03809312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos BID x 10 days
Study NCT03822871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
Study NCT01042197 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
Study NCT01042197 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
Study NCT02652312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
Study NCT01042197 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
Study NCT02652312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 0.15 mg/kg intravenous (IV) will be given as a pre-medication
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 0.15 mg/kg intravenous (IV) will be given as a pre-medication
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: 1.5 μg/kg intraoperative
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fentanyl
Description: 1.5 μg/kg intraoperative
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Description: 0.5 mg/kg IV for endotracheal intubation
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Atracurium
Description: 0.5 mg/kg IV for endotracheal intubation
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium
Description: 1 mg/kg for postoperative analgesia
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: diclofenac sodium
Description: 1 mg/kg for postoperative analgesia
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: desflurane
Description: 1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
Study NCT02652312 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: desflurane
Description: 1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
Study NCT01650818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
Study NCT01650818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy (Stretching/Range-of-motion)
Description: Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
Study NCT01193140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Dose orally twice daily for 7 days, consecutively, every cycle
Study NCT01193140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Dose orally once daily for 5 days, consecutively, every cycle
Study NCT01408667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRC150094
Description: 50 mg Tablets once a day
Study NCT01408667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets once daily
Study NCT00289185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02D
Description: 3-dose intramuscular injection in the thigh
Study NCT00289185 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B®
Description: 3-dose intramuscular injection in the thigh.
Study NCT00289185 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRActHib™
Description: 3-dose intramuscular injection in the thigh.